Incision-free cross-linking marks a new era for keratoconus care
Published: | Updated:
Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.
Rajesh K. Rajpal, MD
Advertisement
Rajesh K. Rajpal, MD, is the founder of See Clearly Vision Group in McLean, Virginia.
Articles by Rajesh K. Rajpal, MD
Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.
Advertisement
Latest Updated Articles
Incision-free cross-linking marks a new era for keratoconus carePublished: October 31st 2025 | Updated: November 9th 2025
- Incision-free cross-linking marks a new era for keratoconus care
Published: October 31st 2025 | Updated: November 9th 2025
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
5